2,3-diisopropyl-cyclopent-2-enone | 100052-27-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,3-diisopropyl-cyclopent-2-enone
• 英文别名: 2,3-Diisopropyl-cyclopent-2-enon；2,3-Di(propan-2-yl)cyclopent-2-en-1-one
• CAS: 100052-27-5
• 化学式: C₁₁H₁₈O
• 分子量: 166.263
• InChiKey: QODMNGQEWMSOLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Pyridobenzazepine compounds and methods for inhibiting mitotic progression
  申请人：Claiborne F. Christopher

  公开号：US20080045501A1

  公开（公告）日：2008-02-21

  This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

  这项发明涉及用于治疗癌症的化合物和方法。具体而言，该发明提供了抑制枢纽激酶的化合物，包括这些化合物的药物组合物，以及使用这些化合物治疗癌症的方法。
• Compounds and methods for inhibiting mitotic progression
  申请人：Claiborne F. Christoper

  公开号：US20070185087A1

  公开（公告）日：2007-08-09

  This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

  本发明涉及化合物和治疗癌症的方法。具体而言，本发明提供抑制极化激酶的化合物，包含该化合物的制药组合物以及使用该化合物治疗癌症的方法。
• COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION
  申请人：Claiborne Christopher F.

  公开号：US20090299060A1

  公开（公告）日：2009-12-03

  This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

  本发明涉及化合物和治疗癌症的方法。具体来说，本发明提供抑制极化激酶的化合物，包含该化合物的制药组合物以及使用该化合物治疗癌症的方法。
• SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：Liu Kun

  公开号：US20110306595A1

  公开（公告）日：2011-12-15

  The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及式(I)的螺环吡咯烷化合物，其是β-分泌酶酶的抑制剂，且在治疗β-分泌酶酶参与的疾病，如阿尔茨海默病中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在治疗β-分泌酶酶参与的疾病中的使用。
• HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS
  申请人：Nanjing Allgen Pharma Co., Ltd.

  公开号：US20140322229A1

  公开（公告）日：2014-10-30

  The present document describes compounds of Formula I, pharmaceutical compositions comprising the same as well as methods of treating diseases such as a cancer, neurological disease, neurodegenerative disorder, stroke, traumatic brain injury, parasitic infection, inflammation or an autoimmune disease with said compounds.

  本文件描述了I式化合物、包含该化合物的药物组合物以及使用该化合物治疗癌症、神经疾病、神经退行性疾病、中风、创伤性脑损伤、寄生虫感染、炎症或自身免疫性疾病的方法。